bioAffinity Technologies, Inc. — Form 8-K

bioAffinity Technologies announced publication of a clinical white paper by CMO Gordon Downie outlining specialty-specific protocols for integrating CyPath Lung into pulmonary nodule evaluation across primary care, pulmonology, and oncology settings. The paper, based on three years of commercial experience since CyPath Lung's market entry, addresses growing demand for lung cancer risk stratification as screening expands and incidental nodules increase. No financial figures, partnerships, regulatory approvals, or material business changes were disclosed.